Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

TOPAS Fecal Incontinence Device Gets Unanimous Support For Approval At FDA Panel

This article was originally published in The Gray Sheet

Executive Summary

All members of the agency's Gastroenterology and Urology Devices Panel were convinced by Astora Women’s Health's evidence in support of PMA approval for the TOPAS mesh implant device for fecal incontinence.


Related Content

Endo Unit Shutdown Could Strand Incontinence Treatment Praised By FDA Panel
Surgeons Slowed Use of Pelvic Mesh Following FDA Warning, N.Y. Study Shows
CDRH Prioritizes Leveraging Real-World And Patient-Preference Data, Enhancing Quality


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst